Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Neoplasms 4Pain, Postoperative 2Hemangioma, Capillary 2Carcinoma, Hepatocellular 2Anxiety Disorders 2Weight Loss 1Vomiting 1Urinary Incontinence, Stress 1Urinary Incontinence 1Shoulder Pain 1SCLC, Limited Stage 1Respiratory Aspiration 1Psychomotor Agitation 1Prostatic Neoplasms 1Premature Birth 1Polycystic Ovary Syndrome 1Pediatric Obesity 1Ovarian Cysts 1Obesity 1Neuromuscular Diseases 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Myofibroma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Multiple Myeloma 1Menstruation Disturbances 1Lymphoma, Follicular 1Lung Neoplasms 1

Interventions

Sodium Bicarbonate 1Saline Solution 1Population Groups 1Intubation 1Health Information Exchange 1Fluoridation 1Fentanyl 1Electrocardiography 1Control Groups 1Bupivacaine 1Atropine 1Anesthesia, General 1Anesthesia, Epidural 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Arrhythmias, Cardiac × Population Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡